Clinical Trial Results:
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Evinacumab in Patients with Homozygous Familial Hypercholesterolemia
Summary
|
|
EudraCT number |
2017-001388-19 |
Trial protocol |
DE FR AT CZ GR IT |
Global end of trial date |
17 Mar 2020
|
Results information
|
|
Results version number |
v2(current) |
This version publication date |
08 Jul 2021
|
First version publication date |
03 Oct 2020
|
Other versions |
v1 |
Version creation reason |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
R1500-CL-1629
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT03399786 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Regeneron Pharmaceuticals, Inc.
|
||
Sponsor organisation address |
777 Old Saw Mill River Road, Tarrytown, NY, United States, 10591
|
||
Public contact |
Clinical Trials Administrator, Regeneron Pharmaceuticals, Inc., clinicaltrials@regeneron.com
|
||
Scientific contact |
Clinical Trials Administrator, Regeneron Pharmaceuticals, Inc., clinicaltrials@regeneron.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
Yes
|
||
EMA paediatric investigation plan number(s) |
EMEA-002298-PIP01-17 | ||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
Yes
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
17 Mar 2020
|
||
Is this the analysis of the primary completion data? |
No
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
17 Mar 2020
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
The primary objective of the study was to demonstrate the reduction of low-density lipoprotein cholesterol (LDL-C) using evinacumab 15 milligrams per kilogram (mg/kg) intravenously (IV) in comparison to placebo after 24 weeks in subjects with homozygous familial hypercholesterolemia (HoFH).
|
||
Protection of trial subjects |
This study was conducted in accordance with the protocol and with the following: Consensus ethical principles derived from international guidelines including the Declaration of Helsinki and Council for International Organizations of Medical Sciences (CIOMS) International Ethical Guidelines; Applicable International Council for Harmonisation (ICH) Good Clinical Practice (GCP) Guidelines; Applicable laws and regulations.
|
||
Background therapy |
Study treatment was added on to the subjects’ stable background lipid modifying therapy. Subjects were on a maximally tolerated statin, ezetimibe, and a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor antibody unless the subject had a documented history of tolerability issues, little or no response to therapy, or other documented reason. | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
18 Jan 2018
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
Yes
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Australia: 4
|
||
Country: Number of subjects enrolled |
Austria: 2
|
||
Country: Number of subjects enrolled |
Canada: 3
|
||
Country: Number of subjects enrolled |
France: 5
|
||
Country: Number of subjects enrolled |
Greece: 4
|
||
Country: Number of subjects enrolled |
Italy: 7
|
||
Country: Number of subjects enrolled |
Japan: 10
|
||
Country: Number of subjects enrolled |
Netherlands: 4
|
||
Country: Number of subjects enrolled |
South Africa: 8
|
||
Country: Number of subjects enrolled |
Ukraine: 8
|
||
Country: Number of subjects enrolled |
United States: 10
|
||
Worldwide total number of subjects |
65
|
||
EEA total number of subjects |
22
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
2
|
||
Adults (18-64 years) |
55
|
||
From 65 to 84 years |
8
|
||
85 years and over |
0
|
|
|||||||||||||||||||
Recruitment
|
|||||||||||||||||||
Recruitment details |
This study was conducted at 30 centers that enrolled subjects in 11 countries in Europe, Asia, North America, and Australia. Randomization was stratified by apheresis treatment status and by region (Japan, Rest of the World [ROW]). | ||||||||||||||||||
Pre-assignment
|
|||||||||||||||||||
Screening details |
A total of 75 subjects were screened and 65 subjects randomized. There were 10 subjects that were considered screen failures. | ||||||||||||||||||
Period 1
|
|||||||||||||||||||
Period 1 title |
Double-blind treatment period (DBTP)
|
||||||||||||||||||
Is this the baseline period? |
Yes | ||||||||||||||||||
Allocation method |
Randomised - controlled
|
||||||||||||||||||
Blinding used |
Double blind | ||||||||||||||||||
Roles blinded |
Subject, Investigator, Monitor, Data analyst, Carer, Assessor | ||||||||||||||||||
Blinding implementation details |
(day 1 to week 20)
|
||||||||||||||||||
Arms
|
|||||||||||||||||||
Are arms mutually exclusive |
Yes
|
||||||||||||||||||
Arm title
|
Placebo IV Q4W (DBTP) | ||||||||||||||||||
Arm description |
Subjects received IV infusion of placebo matched to evinacumab every 4 weeks (Q4W) from day 1 to week 20 in the double-blind treatment period (DBTP). | ||||||||||||||||||
Arm type |
Placebo | ||||||||||||||||||
Investigational medicinal product name |
Placebo
|
||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||
Other name |
|||||||||||||||||||
Pharmaceutical forms |
Infusion
|
||||||||||||||||||
Routes of administration |
Intravenous use
|
||||||||||||||||||
Dosage and administration details |
Subjects received IV infusion of placebo matched to evinacumab Q4W from day 1 to week 20
|
||||||||||||||||||
Arm title
|
Evinacumab 15 mg/kg IV Q4W (DBTP) | ||||||||||||||||||
Arm description |
Subjects received IV infusion of evinacumab at a dose of 15 mg/kg Q4W from day 1 to week 20 in the double-blind treatment period (DBTP). | ||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||
Investigational medicinal product name |
Evinacumab
|
||||||||||||||||||
Investigational medicinal product code |
REGN1500
|
||||||||||||||||||
Other name |
|||||||||||||||||||
Pharmaceutical forms |
Infusion
|
||||||||||||||||||
Routes of administration |
Intravenous use
|
||||||||||||||||||
Dosage and administration details |
Subjects received IV infusion of evinacumab at a dose of 15 mg/kg Q4W from day 1 to week 20
|
||||||||||||||||||
|
|||||||||||||||||||
Period 2
|
|||||||||||||||||||
Period 2 title |
Open-label treatment period (OLTP)
|
||||||||||||||||||
Is this the baseline period? |
No | ||||||||||||||||||
Allocation method |
Not applicable
|
||||||||||||||||||
Blinding used |
Not blinded | ||||||||||||||||||
Arms
|
|||||||||||||||||||
Are arms mutually exclusive |
Yes
|
||||||||||||||||||
Arm title
|
Placebo IV Q4W (OLTP) | ||||||||||||||||||
Arm description |
All subjects in the placebo arm who completed the double-blind treatment period (DBTP) received IV infusion of evinacumab at a dose of 15 mg/kg Q4W from week 24 to week 44 in the open-label treatment period (OLTP). | ||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||
Investigational medicinal product name |
Evinacumab
|
||||||||||||||||||
Investigational medicinal product code |
REGN1500
|
||||||||||||||||||
Other name |
|||||||||||||||||||
Pharmaceutical forms |
Infusion
|
||||||||||||||||||
Routes of administration |
Intravenous use
|
||||||||||||||||||
Dosage and administration details |
All subjects received IV infusion of evinacumab at a dose of 15 mg/kg Q4W from week 24 to week 44.
|
||||||||||||||||||
Arm title
|
Evinacumab 15 mg/kg IV Q4W (OLTP) | ||||||||||||||||||
Arm description |
All subjects who completed the double-blind treatment period (DBTP) received IV infusion of evinacumab at a dose of 15 mg/kg Q4W from week 24 to week 44 in the open-label treatment period (OLTP). | ||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||
Investigational medicinal product name |
Evinacumab
|
||||||||||||||||||
Investigational medicinal product code |
REGN1500
|
||||||||||||||||||
Other name |
|||||||||||||||||||
Pharmaceutical forms |
Infusion
|
||||||||||||||||||
Routes of administration |
Intravenous use
|
||||||||||||||||||
Dosage and administration details |
All subjects received IV infusion of evinacumab at a dose of 15 mg/kg Q4W from week 24 to week 44.
|
||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Placebo IV Q4W (DBTP)
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects received IV infusion of placebo matched to evinacumab every 4 weeks (Q4W) from day 1 to week 20 in the double-blind treatment period (DBTP). | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Evinacumab 15 mg/kg IV Q4W (DBTP)
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects received IV infusion of evinacumab at a dose of 15 mg/kg Q4W from day 1 to week 20 in the double-blind treatment period (DBTP). | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Placebo IV Q4W (DBTP)
|
||
Reporting group description |
Subjects received IV infusion of placebo matched to evinacumab every 4 weeks (Q4W) from day 1 to week 20 in the double-blind treatment period (DBTP). | ||
Reporting group title |
Evinacumab 15 mg/kg IV Q4W (DBTP)
|
||
Reporting group description |
Subjects received IV infusion of evinacumab at a dose of 15 mg/kg Q4W from day 1 to week 20 in the double-blind treatment period (DBTP). | ||
Reporting group title |
Placebo IV Q4W (OLTP)
|
||
Reporting group description |
All subjects in the placebo arm who completed the double-blind treatment period (DBTP) received IV infusion of evinacumab at a dose of 15 mg/kg Q4W from week 24 to week 44 in the open-label treatment period (OLTP). | ||
Reporting group title |
Evinacumab 15 mg/kg IV Q4W (OLTP)
|
||
Reporting group description |
All subjects who completed the double-blind treatment period (DBTP) received IV infusion of evinacumab at a dose of 15 mg/kg Q4W from week 24 to week 44 in the open-label treatment period (OLTP). |
|
|||||||||||||
End point title |
Percent Change in Calculated Low-Density Lipoprotein Cholesterol (LDL-C) from Baseline to Week 24 (Intent-to-Treat [ITT] Estimand) | ||||||||||||
End point description |
Percent change was calculated as 100x(calculated LDL-C value at Week 24 - calculated LDL-C value at baseline)/calculated LDL-C value at baseline. The baseline LDL-C value was the last calculated LDL-C value obtained before the first dose of double-blind-study drug. The calculated LDL-C at week 24 was the LDL-C value obtained within the week 24 efficacy analysis window, regardless of adherence to treatment and subsequent therapies (intent-to-treat [ITT] estimand). The ITT population included all randomized subjects who received at least one dose or part of a dose of double-blind study drug. Subjects in the ITT population were analyzed according to the treatment group allocated by randomization (i.e., as randomized subject group).
|
||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
Week 24
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Placebo IV Q4W, Evinacumab 15 mg/kg IV Q4W | ||||||||||||
Statistical analysis description |
Confidence interval (CI) with p-value was based on-treatment group difference of least squares (LS) means using mixed-effect model repeat measurement (MMRM), randomization strata, treatment/strata/baseline value-by-time point interaction and continuous fixed covariates of baseline calculated LDL-C value.
|
||||||||||||
Comparison groups |
Placebo IV Q4W (DBTP) v Evinacumab 15 mg/kg IV Q4W (DBTP)
|
||||||||||||
Number of subjects included in analysis |
65
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
< 0.0001 | ||||||||||||
Method |
Mixed-effect Model Repeat Measure (MMRM) | ||||||||||||
Parameter type |
Least Squares (LS) Mean Difference | ||||||||||||
Point estimate |
-49
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
-65 | ||||||||||||
upper limit |
-33.1 | ||||||||||||
Variability estimate |
Standard error of the mean
|
||||||||||||
Dispersion value |
8
|
|
|||||||||||||
End point title |
Percent Change in Apolipoprotein B (Apo B) from Baseline to Week 24 (ITT Estimand) | ||||||||||||
End point description |
Percent change in Apo B from baseline at Week 24 in the DBTP was reported; value obtained regardless of adherence to study treatment and subsequent therapies (ITT estimand). ITT population included all randomized subjects who received at least one dose or part of a dose of double-blind study drug. Subjects in the ITT population were analyzed according to the treatment group allocated by randomization (i.e., as randomized subject group).
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Week 24
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Placebo IV Q4W, Evinacumab 15 mg/kg IV Q4W | ||||||||||||
Statistical analysis description |
A 2-sided hierarchical testing procedure was used for the secondary endpoints in a pre-specified order to control type I error. The hierarchical testing sequence continued only when the previous endpoint was statistically significant at 0.05 level. CI with p-value was based on-treatment group difference of LS means using MMRM, randomization strata, treatment/strata/baseline value-by-time point interaction and continuous fixed covariates of baseline calculated Apo B value.
|
||||||||||||
Comparison groups |
Placebo IV Q4W (DBTP) v Evinacumab 15 mg/kg IV Q4W (DBTP)
|
||||||||||||
Number of subjects included in analysis |
65
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
< 0.0001 | ||||||||||||
Method |
Mixed-effect Model Repeat Measure (MMRM) | ||||||||||||
Parameter type |
Least Squares (LS) Mean Difference | ||||||||||||
Point estimate |
-36.9
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
-48.6 | ||||||||||||
upper limit |
-25.2 | ||||||||||||
Variability estimate |
Standard error of the mean
|
||||||||||||
Dispersion value |
5.9
|
|
|||||||||||||
End point title |
Percent Change in Non-High-Density Lipoprotein Cholesterol (non-HDL-C) from Baseline to Week 24 (ITT Estimand) | ||||||||||||
End point description |
Percent change from baseline in non-HDL-C at Week 24 in the DBTP was reported; value obtained regardless of adherence to study treatment and subsequent therapies (ITT estimand). ITT population included all randomized subjects who received at least one dose or part of a dose of double-blind study drug. Subjects in the ITT population were analyzed according to the treatment group allocated by randomization (i.e., as randomized subject group).
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Week 24
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Placebo IV Q4W, Evinacumab 15 mg/kg IV Q4W | ||||||||||||
Statistical analysis description |
A 2-sided hierarchical testing procedure was used for the secondary endpoints in a pre-specified order to control type I error. The hierarchical testing sequence continued only when the previous endpoint was statistically significant at 0.05 level. CI with p-value was based on-treatment group difference of LS means using MMRM, randomization strata, treatment/strata/baseline value-by-time point interaction and continuous fixed covariates of baseline calculated non-HDL-C value.
|
||||||||||||
Comparison groups |
Placebo IV Q4W (DBTP) v Evinacumab 15 mg/kg IV Q4W (DBTP)
|
||||||||||||
Number of subjects included in analysis |
65
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
< 0.0001 | ||||||||||||
Method |
Mixed-effect Model Repeat Measure (MMRM) | ||||||||||||
Parameter type |
Least Squares (LS) Mean Difference | ||||||||||||
Point estimate |
-51.7
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
-64.8 | ||||||||||||
upper limit |
-38.5 | ||||||||||||
Variability estimate |
Standard error of the mean
|
||||||||||||
Dispersion value |
6.6
|
|
|||||||||||||
End point title |
Percent Change in Total Cholesterol (TC) from Baseline to Week 24 (ITT Estimand) | ||||||||||||
End point description |
Percent change in TC from baseline at Week 24 in the DBTP was reported; value obtained regardless of adherence to study treatment and subsequent therapies (ITT estimand). ITT population included all randomized subjects who received at least one dose or part of a dose of double-blind study drug. Subjects in the ITT population were analyzed according to the treatment group allocated by randomization (i.e., as randomized subject group).
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Week 24
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Placebo IV Q4W, Evinacumab 15 mg/kg IV Q4W | ||||||||||||
Statistical analysis description |
A 2-sided hierarchical testing procedure was used for the secondary endpoints in a pre-specified order to control type I error. The hierarchical testing sequence continued only when the previous endpoint was statistically significant at 0.05 level. CI with p-value was based on-treatment group difference of LS means using MMRM, randomization strata, treatment/strata/baseline value-by-time point interaction and continuous fixed covariates of baseline calculated TC value.
|
||||||||||||
Comparison groups |
Placebo IV Q4W (DBTP) v Evinacumab 15 mg/kg IV Q4W (DBTP)
|
||||||||||||
Number of subjects included in analysis |
65
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
< 0.0001 | ||||||||||||
Method |
Mixed-effect Model Repeat Measure (MMRM) | ||||||||||||
Parameter type |
Least Squares (LS) Mean Difference | ||||||||||||
Point estimate |
-48.4
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
-58.7 | ||||||||||||
upper limit |
-38.1 | ||||||||||||
Variability estimate |
Standard error of the mean
|
||||||||||||
Dispersion value |
5.1
|
|
|||||||||||||
End point title |
Percentage of Subjects with ≥30% Reduction in Calculated Low-Density Lipoprotein Cholesterol (LDL-C) at Week 24 (ITT Estimand) | ||||||||||||
End point description |
Percentage of subjects who achieved reduction in calculated LDL-C ≥30% at Week 24 in the DBTP was reported; value obtained regardless of adherence to study treatment and subsequent therapies (ITT estimand). ITT population included all randomized subjects who received at least one dose or part of a dose of double-blind study drug. Subjects in the ITT population were analyzed according to the treatment group allocated by randomization (i.e., as randomized subject group).
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
At Week 24
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Placebo IV Q4W, Evinacumab 15 mg/kg IV Q4W | ||||||||||||
Statistical analysis description |
A 2-sided hierarchical testing procedure was used for secondary endpoints in pre-specified order to control type I error.Testing sequence continued only when previous endpoint was statistically significant at 0.05.Multiple imputation addressed missing data at week 24.Combined estimate for odds ratio obtained by Rubin's formulae.Logistic regression models stratified by randomized strata include fixed categorical effect of treatment group & continuous fixed covariate of baseline calculated LDL-C.
|
||||||||||||
Comparison groups |
Placebo IV Q4W (DBTP) v Evinacumab 15 mg/kg IV Q4W (DBTP)
|
||||||||||||
Number of subjects included in analysis |
65
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority [1] | ||||||||||||
P-value |
< 0.0001 | ||||||||||||
Method |
Logistic Regression Models Analyses | ||||||||||||
Parameter type |
Odds ratio (OR) | ||||||||||||
Point estimate |
25.2
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
5.7 | ||||||||||||
upper limit |
110.5 | ||||||||||||
Notes [1] - A 2-step multiple imputation method addressed missing values (seeds = 1629 & 9261 with number of imputations = 100 in first and number of imputation=1 in second step). |
|
|||||||||||||
End point title |
Percentage of Subjects with ≥50% Reduction in Calculated Low-Density Lipoprotein Cholesterol (LDL-C) at Week 24 (ITT Estimand) | ||||||||||||
End point description |
Percentage of subjects who achieved reduction in calculated LDL-C ≥ 50% at Week 24 in the DBTP was reported; value obtained regardless of adherence to study treatment and subsequent therapies (ITT estimand). ITT population included all randomized subjects who received at least one dose or part of a dose of double-blind study drug. Subjects in the ITT population were analyzed according to the treatment group allocated by randomization (i.e., as randomized subject group).
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
At Week 24
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Placebo IV Q4W, Evinacumab 15 mg/kg IV Q4W | ||||||||||||
Statistical analysis description |
A 2-sided hierarchical testing procedure was used for secondary endpoints in pre-specified order to control type I error.Testing sequence continued only when previous endpoint was statistically significant at 0.05.Multiple imputation addressed missing data at week 24.Combined estimate for odds ratio obtained by Rubin's formulae.Logistic regression models stratified by randomized strata include fixed categorical effect of treatment group & continuous fixed covariate of baseline calculated LDL-C.
|
||||||||||||
Comparison groups |
Placebo IV Q4W (DBTP) v Evinacumab 15 mg/kg IV Q4W (DBTP)
|
||||||||||||
Number of subjects included in analysis |
65
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority [2] | ||||||||||||
P-value |
= 0.0028 | ||||||||||||
Method |
Logistic Regression Models Analyses | ||||||||||||
Parameter type |
Odds ratio (OR) | ||||||||||||
Point estimate |
24.2
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
3 | ||||||||||||
upper limit |
195.6 | ||||||||||||
Notes [2] - A 2-step multiple imputation method addressed missing values (seeds = 1629 & 9261 with number of imputations = 100 in first and number of imputation=1 in second step). |
|
|||||||||||||
End point title |
Absolute Change in Calculated Low-Density Lipoprotein Cholesterol (LDL-C) from Baseline to Week 24 (ITT Estimand) | ||||||||||||
End point description |
Absolute change in calculated LDL-C from baseline at Week 24 in the DBTP was reported; value obtained regardless of adherence to study treatment and subsequent therapies (ITT estimand). ITT population included all randomized subjects who received at least one dose or part of a dose of double-blind study drug. Subjects in the ITT population were analyzed according to the treatment group allocated by randomization (i.e., as randomized subject group).
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Week 24
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Placebo IV Q4W, Evinacumab 15 mg/kg IV Q4W | ||||||||||||
Statistical analysis description |
A 2-sided hierarchical testing procedure was used for the secondary endpoints in a pre-specified order to control type I error. The hierarchical testing sequence continued only when the previous endpoint was statistically significant at 0.05 level. CI with p-value was based on-treatment group difference of LS means using MMRM, randomization strata, treatment/strata/baseline value-by-time point interaction and continuous fixed covariates of baseline calculated LDL-C value.
|
||||||||||||
Comparison groups |
Placebo IV Q4W (DBTP) v Evinacumab 15 mg/kg IV Q4W (DBTP)
|
||||||||||||
Number of subjects included in analysis |
65
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
< 0.0001 | ||||||||||||
Method |
Mixed-effect Model Repeat Measure (MMRM) | ||||||||||||
Parameter type |
Least Squares (LS) Mean Difference | ||||||||||||
Point estimate |
-132.1
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
-175.3 | ||||||||||||
upper limit |
-88.9 | ||||||||||||
Variability estimate |
Standard error of the mean
|
||||||||||||
Dispersion value |
21.5
|
|
|||||||||||||
End point title |
Percentage of Subjects Who Met United States (US) Apheresis Eligibility Criteria at Week 24 (ITT Estimand) | ||||||||||||
End point description |
US apheresis eligibility criteria included subjects who had inadequate response to diet and LMTs after 6 months of treatment and with Functional Homozygous familial hypercholesterolemia (HoFH) or Heterozygous familial hypercholesterolemia (HeFH) (with 0-1 risk factor) with LDL-C ≥ 300 mg/dL (7.77 mmol/L). Percentage of subjects who met US apheresis eligibility criteria at Week 24 in the DBTP was reported; value obtained regardless of adherence to study treatment and subsequent therapies (ITT estimand). ITT population included all randomized subjects who received at least one dose or part of a dose of double-blind study drug. Subjects in the ITT population were analyzed according to the treatment group allocated by randomization (i.e., as randomized subject group).
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
At Week 24
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Placebo IV Q4W, Evinacumab 15 mg/kg IV Q4W | ||||||||||||
Statistical analysis description |
A 2-sided hierarchical testing procedure was used for the secondary endpoints in a pre-specified order to control type I error. The hierarchical testing sequence continued only when the previous endpoint was statistically significant at 0.05 level. Combined estimate for odds ratio was obtained by using Rubin's formulae. Logistic regression models stratified the fixed categorical effect of treatment group and the continuous fixed covariate of baseline calculated LDL-C value.
|
||||||||||||
Comparison groups |
Evinacumab 15 mg/kg IV Q4W (DBTP) v Placebo IV Q4W (DBTP)
|
||||||||||||
Number of subjects included in analysis |
65
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority [3] | ||||||||||||
P-value |
= 0.0845 | ||||||||||||
Method |
Logistic Regression Models Analyses | ||||||||||||
Parameter type |
Odds ratio (OR) | ||||||||||||
Point estimate |
0.1
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
0 | ||||||||||||
upper limit |
1.3 | ||||||||||||
Notes [3] - A 2-step multiple imputation method addressed missing values (seeds = 1629 & 9261 with number of imputations = 100 in first and number of imputation=1 in second step). |
|
|||||||||||||
End point title |
Percentage of Subjects with Low-Density Lipoprotein Cholesterol (LDL-C) <100 milligrams per deciliter (mg/dL) (2.59 millimoles per liter [mmol/L]) at Week 24 (ITT Estimand) | ||||||||||||
End point description |
Percentage of subjects with LDL-C value <100 mg/dL (2.59 mmol/L) in the DBTP at Week 24 was reported; value obtained regardless of adherence to study treatment and subsequent therapies (ITT estimand). ITT population included all randomized subjects who received at least one dose or part of a dose of double-blind study drug. Subjects in the ITT population were analysed according to the treatment group allocated by randomization (i.e., as randomized subject group).
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
At Week 24
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Placebo IV Q4W, Evinacumab 15 mg/kg IV Q4W | ||||||||||||
Statistical analysis description |
A 2-sided hierarchical testing procedure was used for the secondary endpoints in a pre-specified order to control type I error. The hierarchical testing sequence continued only when the previous endpoint was statistically significant at 0.05 level. Combined estimate for odds ratio was obtained by using Rubin's formulae. Logistic regression models stratified the fixed categorical effect of treatment group and the continuous fixed covariate of baseline calculated LDL-C value.
|
||||||||||||
Comparison groups |
Evinacumab 15 mg/kg IV Q4W (DBTP) v Placebo IV Q4W (DBTP)
|
||||||||||||
Number of subjects included in analysis |
65
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority [4] | ||||||||||||
P-value |
= 0.0203 [5] | ||||||||||||
Method |
Logistic Regression Models Analyses | ||||||||||||
Parameter type |
Odds ratio (OR) | ||||||||||||
Point estimate |
5.7
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
1.3 | ||||||||||||
upper limit |
24.9 | ||||||||||||
Notes [4] - A 2-step multiple imputation method addressed missing values (seeds = 1629 & 9261 with number of imputations = 100 in first and number of imputation=1 in second step). [5] - The p-value is nominal for descriptive purpose only due to statistical hypothesis testing terminated previously. |
|
|||||||||||||
End point title |
Percentage of Subjects Who Met European Union (EU) Apheresis Eligibility Criteria at Week 24 (ITT Estimand) | ||||||||||||
End point description |
EU apheresis eligibility criteria included subjects who had inadequate response to diet and Lipid modifying therapies (LMTs) after 3 months of treatment, Primary prevention: Subjects with Familial hypercholesterolemia (FH) with LDL-C >160 mg/dL (4.2 mmol/L) and Cardiovascular (CV) events in close relatives. Secondary prevention: Subjects with progressive CV events with LDL-C > 120 to 130 mg/dL (3.1-3.4 mmol/L). Percentage of subjects who met EU apheresis eligibility criteria at Week 24 in the DBTP was reported; value obtained regardless of adherence to study treatment and subsequent therapies (ITT estimand). ITT population included all randomized subjects who received at least one dose or part of a dose of double-blind study drug. Subjects in the ITT population were analyzed according to the treatment group allocated by randomization (i.e., as randomized subject group).
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
At Week 24
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Placebo IV Q4W, Evinacumab 15 mg/kg IV Q4W | ||||||||||||
Statistical analysis description |
A 2-sided hierarchical testing procedure was used for the secondary endpoints in a pre-specified order to control type I error. The hierarchical testing sequence continued only when the previous endpoint was statistically significant at 0.05 level. Combined estimate for odds ratio was obtained by using Rubin's formulae. Logistic regression models stratified the fixed categorical effect of treatment group and the continuous fixed covariate of baseline calculated LDL-C value.
|
||||||||||||
Comparison groups |
Placebo IV Q4W (DBTP) v Evinacumab 15 mg/kg IV Q4W (DBTP)
|
||||||||||||
Number of subjects included in analysis |
65
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority [6] | ||||||||||||
P-value |
= 0.0004 [7] | ||||||||||||
Method |
Logistic Regression Models Analysis | ||||||||||||
Parameter type |
Odds ratio (OR) | ||||||||||||
Point estimate |
0.1
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
0 | ||||||||||||
upper limit |
0.3 | ||||||||||||
Notes [6] - A 2-step multiple imputation method addressed missing values (seeds = 1629 & 9261 with number of imputations = 100 in first and number of imputation=1 in second step). [7] - The p-value is nominal for descriptive purpose only due to statistical hypothesis testing terminated previously. |
|
|||||||||||||
End point title |
Percentage of Subjects with Calculated Low-Density Lipoprotein Cholesterol (LDL-C) <70 mg/dL (1.81 mmol/L) at Week 24 (ITT Estimand) | ||||||||||||
End point description |
Percentage of subjects with LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 in the DBTP was reported; value obtained regardless of adherence to study treatment and subsequent therapies (ITT estimand). ITT population included all randomized subjects who received at least one dose or part of a dose of double-blind study drug. Subjects in the ITT population were analyzed according to the treatment group allocated by randomization (i.e., as randomized subject group).
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
At Week 24
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Percent Change in Fasting Triglycerides (TG) from Baseline to Week 24 (ITT Estimand) | ||||||||||||
End point description |
Percent change from baseline in TG at Week 24 in the DBTP was reported; value obtained regardless of adherence to study treatment and subsequent therapies (ITT estimand). ITT population included all randomized subjects who received at least one dose or part of a dose of double-blind study drug. Subjects in the ITT population were analyzed according to the treatment group allocated by randomization (i.e., as randomized subject group).
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Week 24
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Percent Change in Lipoprotein A (Lp[a]) from Baseline to Week 24 (ITT Estimand) | ||||||||||||
End point description |
Percent change in Lp(a) from baseline at Week 24 in the DBTP was reported; value obtained regardless of adherence to study treatment and subsequent therapies (ITT estimand). ITT population included all randomized subjects who received at least one dose or part of a dose of double-blind study drug. Subjects in the ITT population were analyzed according to the treatment group allocated by randomization (i.e., as randomized subject group).
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Week 24
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Absolute Change in Apolipoprotein B (Apo B) from Baseline to Week 24 (ITT Estimand) | ||||||||||||
End point description |
Absolute change in Apo B from baseline at Week 24 in the DBTP was reported; value obtained regardless of adherence to study treatment and subsequent therapies (ITT estimand). ITT population included all randomized subjects who received at least one dose or part of a dose of double-blind study drug. Subjects in the ITT population were analyzed according to the treatment group allocated by randomization (i.e., as randomized subject group).
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Week 24
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Absolute Change in Non-High-Density Lipoprotein Cholesterol (non-HDL-C) from Baseline to Week 24 (ITT Estimand) | ||||||||||||
End point description |
Absolute change in non-HDL-C from baseline at Week 24 in the DBTP was reported; value obtained regardless of adherence to study treatment and subsequent therapies (ITT estimand). ITT population included all randomized subjects who received at least one dose or part of a dose of double-blind study drug. Subjects in the ITT population were analyzed according to the treatment group allocated by randomization (i.e., as randomized subject group).
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Week 24
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Absolute Change in Total Cholesterol (TC) from Baseline to Week 24 (ITT Estimand) | ||||||||||||
End point description |
Absolute change in TC from baseline at Week 24 in the DBTP was reported; value obtained regardless of adherence to study treatment and subsequent therapies (ITT estimand). ITT population included all randomized subjects who received at least one dose or part of a dose of double-blind study drug. Subjects in the ITT population were analyzed according to the treatment group allocated by randomization (i.e., as randomized subject group).
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Week 24
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Percent Change in Apolipoprotein CIII (Apo CIII) from Baseline to Week 24 (ITT Estimand) | ||||||||||||
End point description |
Percent change in Apo CIII from baseline at Week 24 in the DBTP was reported; value obtained regardless of adherence to study treatment and subsequent therapies (ITT estimand). ITT population included all randomized subjects who received at least one dose or part of a dose of double-blind study drug. Subjects in the ITT population were analyzed according to the treatment group allocated by randomization (i.e., as randomized subject group).
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Week 24
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
All Adverse Events (AEs) were collected from signature of the informed consent form up until end of study (Week 68) regardless of seriousness or relationship to investigational product (IP).
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse event reporting additional description |
For purpose of safety analysis, arm assignments for participants in Safety Set were based on actual treatment received, such that 1 participant assigned to Placebo arm who inadvertently received evinacumab 15mg/kg was included in Evinacumab 15mg/kg arm.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
22
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Placebo IV Q4W (DBTP)
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects received IV infusion of placebo matched to evinacumab every 4 weeks (Q4W) from day 1 to week 20 in the double-blind treatment period (DBTP). | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Evinacumab 15 mg (DBTP)
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects received IV infusion of evinacumab at a dose of 15 mg/kg Q4W from day 1 to week 20 in the double-blind treatment period (DBTP). | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Placebo IV Q4W (OLTP)
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
All subjects in the placebo arm who completed the double-blind treatment period (DBTP) received IV infusion of evinacumab at a dose of 15 mg/kg Q4W from week 24 to week 44 in the open-label treatment period (OLTP). | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Evinacumab 15 mg (OLTP)
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
All subjects in the evinacumab arm who completed the double-blind treatment period (DBTP) received IV infusion of evinacumab at a dose of 15 mg/kg Q4W from week 24 to week 44 in the open-label treatment period (OLTP). | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
07 Dec 2017 |
1. Added EuroQol-5D (EQ-5D) and Hospital Anxiety and Depression Scale (HADS) Quality of Life (QOL) questionnaires and an EQ-5D and HADS objective and exploratory endpoint to allow assessment of quality of life in this population. 2. Added Lipid Panel and Specialty Lipid Panel assessments and assessments of hematology, blood chemistry, and creatinine phosphokinase for the follow-up period. 3. Added a criterion excluding patients with LDL-C level <70 mg/dL as that was the goal for FH subjects. 4. Updated anti-drug antibody (ADA) variables and added a statement for follow-up of subjects positive in the ADA assay. 5. Added ADA sample at week 4. 6. Modified timing of one assessment for weight and one assessment for Pharmacokinetics (PK). |
||
21 Jun 2018 |
1. Expanded Risk/Benefit section to include risk/benefit assessment of the combination of Evinacumab and Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, including alirocumab for the treatment of subjects with homozygous familial hypercholesterolemia (HoFH). 2. Clarified that subjects enrolling from R727-CL-1628 (2017-000351-95) will continue to receive alirocumab 150 mg every 2 weeks (Q2W). |
||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |